Xingjun Meng1,#, Zhihui Cao2,#, Renfeng Liu3,#, Kai Zheng4, Shuai Ding5, Yuefan Gu4, Yonghua Chen6, Jun Lv7, Ping Li8, Li Zhou9, Wenbo Wang10, Shiliang Ji11, Hui He12,*, Hui Yang9,*
Oncologie, Vol.24, No.2, pp. 283-294, 2022, DOI:10.32604/oncologie.2022.021259
- 29 June 2022
Abstract It is widely accepted that tumor metastasis is the dominant factor leading to cancer-related death. Tumor metastasis is mediated by cell invasion, blood circulation and lymphatic circulation. Paclitaxel, as a common anti-tumor
drug and a mitotic inhibitor, promotes microtubule assembly and inhibits microtubule depolymerization. In addition, ticagrelor, an anti-platelet drug, is used to treat acute coronary syndrome. Increasing numbers of studies
have reported that platelets can facilitate tumor metastasis. Therefore, inhibiting the effects of platelets can serve
as a novel therapeutic strategy for cancer. To explore the effect of anti-tumor and anti-platelet drugs on tumor More >
Login
Register
